CRISPR Therapy Raises Fetal Hemoglobin in Sickle Cell Disease - Takeaway - MDSpire
Feature

CRISPR Therapy Raises Fetal Hemoglobin in Sickle Cell Disease

An investigational Cas12a-edited stem cell treatment sharply boosted HbF and largely eliminated vaso-occlusive crises in an early trial

  • April 13, 2026

  • 2 min

Share

  • 1

    Gene-editing therapy renizgamglogene autogedtemcel shows promising results in sickle cell patients.

  • 2

    Mean total hemoglobin increased from 9.8 g/dL to 13.8 g/dL.

  • 3

    27 out of 28 patients had no severe vaso-occlusive events post-treatment.

  • 4

    Fetal hemoglobin levels rose from 2.5% to 48.1%.

  • 5

    Engraftment displayed robust levels of recovery for neutrophils and platelets.

  • 6

    Safety findings align with traditional treatments like autologous stem cell transplantation.

  • 7

    Study cut short due to development priorities but results are promising.

Original Source(s)

CRISPR Therapy Raises Fetal Hemoglobin in Sickle Cell Disease

  • April 13, 2026

Related Content

Study Examines Surgery vs. Surveillance for Vascular Rings

A recent study from Phoenix Children’s cardiologists and cardiothoracic surgeons examines how best to manage children with vascular rings, comparing surgical treatment with observation over time.

  • by

  • April 9, 2026

  • 2 min
Phoenix Children’s Earns National Designation for Pediatric Pulmonary Hypertension Care

Phoenix Children’s is now designated a PPHNet Network Site one of only 14 pediatric centers in the US and Canada, recognized for excellence in pediatric pulmonary hypertension care.

  • by

  • April 9, 2026

  • 2 min
Dannah Raz, MD, MPH, Named to Modern Healthcare’s 40 Under 40

Phoenix Children’s, one of the top-ranked pediatric health systems in the West, announced that Dannah Raz, MD, MPH, division chief of developmental and behavioral pediatrics, has been named to Modern Healthcare’s 40 Under 40 for 2026

  • by

  • April 9, 2026

  • 3 min